SOBR.NASDAQSobr Safe, INC

10-K: SOBR Safe, Inc. Files 10-K Annual Report, Details Financials and Business Strategy for 2023

Sentiment:

Annual Results


SOBR Safe, Inc. released its 2023 annual report, highlighting the commercial launch of its wearable alcohol detection device and ongoing efforts to expand its market presence.

Capital raiseThe company received approximately $3,000,000 in gross proceeds from a debt offering of convertible senior notes.The company may need additional capital in the future to support its operations and growth.
Worse than expectedThe company's net loss of $10,214,721 and accumulated deficit of $87,765,981 indicate that the company is not yet profitable and is still in the early stages of commercialization.The company's cash burn rate of $425,000 per month and limited cash on hand of $2,790,147 raise concerns about its ability to continue as a going concern.The company's reliance on third-party manufacturers and potential supply chain issues also pose risks to its future performance.

Summary

  • SOBR Safe, Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2023.
  • The company provides non-invasive alcohol detection technology and a data platform.
  • Their products include the SOBRcheck stationary device and the SOBRsure wearable band.
  • The company's mission is to save lives, increase productivity, and positively impact behavior.
  • SOBRsafe technology is being targeted for use in behavioral health, justice, commercial environments, and individual use.
  • The company began commercial sales of the SOBRsure device in late September 2023, generating initial revenues in October 2023.
  • The company has six channel partners to augment sales and marketing efforts.
  • As of March 29, 2024, the company has 14 full-time employees.
  • The company reported a net loss of $10,214,721 for 2023, compared to a net loss of $12,354,930 in 2022.
  • Revenue increased to $157,292 in 2023 from $35,322 in 2022.
  • The company had cash on hand of $2,790,147 as of December 31, 2023.
  • The company's current normalized monthly operating cash flow burn rate is approximately $425,000.
  • The company has an accumulated deficit of $87,765,981 as of December 31, 2023.
  • The company received approximately $3,000,000 in gross proceeds from a debt offering of convertible senior notes.
  • The company is exploring licensing and integration opportunities for its technology.

Sentiment

Score: 4

Explanation: The document shows some positive signs with revenue growth and product launch, but the significant losses, high cash burn, and going concern uncertainty create a negative outlook. The company is still in a high-risk phase.

Positives

  • The company successfully launched its second product, the SOBRsure wearable band, and began generating revenue from it.
  • Revenue increased significantly year-over-year, indicating growing market traction.
  • The company reduced its net loss compared to the previous year.
  • The company has established partnerships to expand its sales and marketing efforts.
  • The company has a portfolio of patents and pending patent applications to protect its technology.
  • The company has a diverse board of directors.

Negatives

  • The company continues to experience significant losses from operations.
  • The company has a substantial accumulated deficit of $87,765,981.
  • The company's cash burn rate is approximately $425,000 per month.
  • The company's current cash balance may not be sufficient to cover operating activities for the next twelve months.
  • The company is dependent on third-party manufacturers for its products.
  • The company has a limited operating history.

Risks

  • The company has a limited operating history and may not be able to achieve profitability.
  • The company may not be able to meet its future capital needs.
  • The company's technology may not be effective at detecting alcohol.
  • The company faces intense competition in its markets.
  • The company relies on third-party manufacturers and may experience supply chain issues.
  • The company's products may contain defects or be installed incorrectly.
  • The company may not be able to adequately protect its proprietary rights.
  • The company's internal controls may not be effective.
  • The company's stock price may be volatile and may be affected by market conditions beyond its control.
  • The company may not be able to maintain its listing on the Nasdaq.

Future Outlook

The company anticipates that its outsourced manufacturers can adequately support an increase in sales for the foreseeable future and expects to continue to evolve its products and software to meet diverse customer requirements across varied markets. The company also anticipates hiring an expert in licensing and integration in 2024 to formulate and execute a global expansion plan.

Management Comments

  • Management believes that cash balances and positive working capital at December 31, 2023 do not provide adequate operating capital for operating activities for the next twelve months after the date these financial statements are issued.
  • Management believes actions presently being taken to generate product and services revenues, and positive cash flows, in addition to the Companys plans and ability to access capital sources and implement additional expense reduction tactics to preserve working capital, provide the opportunity for the Company to continue as a going concern as of December 31, 2023.

Industry Context

The company is positioning itself as a leading provider of preventative transdermal alcohol detection systems, differentiating itself from competitors focused on breathalyzers and ankle monitors. The company is targeting various markets including behavioral health, justice, and commercial environments, which are all areas with a growing need for alcohol monitoring solutions.

Comparison to Industry Standards

  • The company's revenue growth from $35,322 to $157,292 year-over-year indicates a positive trend, but it is still in the early stages of commercialization compared to established competitors.
  • The company's net loss of $10,214,721 is significant, and it will need to demonstrate a clear path to profitability to be competitive with other companies in the industry.
  • The company's focus on transdermal technology is a differentiator, but it will need to prove its effectiveness and reliability against established breathalyzer and ankle monitor technologies.
  • The company's cash burn rate of $425,000 per month is high, and it will need to manage its expenses carefully to ensure its long-term viability.
  • The company's reliance on third-party manufacturers is a common practice in the industry, but it also introduces supply chain risks that need to be managed effectively.
  • The company's intellectual property portfolio is a key asset, but it will need to continue to innovate and protect its technology to maintain a competitive edge.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Chief Financial OfficerJerry WenzelChristopher Whitaker2024-01Jerry Wenzel's employment agreement ended on January 1, 2024.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Code of EthicsThe Board of Directors adopted an amended and restated code of business conduct and ethics applicable to employees, directors and officers.2022-04-22Ensures compliance with applicable U.S. federal securities laws and Nasdaq corporate governance rules.
Compensation Recovery PolicyThe Board of Directors adopted a clawback policy for the recovery of erroneously awarded compensation from Executive Officers.2023-12-01Ensures compliance with Nasdaq rules and Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934.

Legal Proceedings

  • The company is involved in a lawsuit filed in 2006 for breach of contract, with a default judgment against the company.
  • The company was named as a party to a complaint filed in Oakland County Court, Michigan by a former employee claiming breach of contract, unlawful termination and promissory estoppel.

Related Party Transactions

  • David Gandini's sons, Greg Gandini and Robert Gandini, are employees of SOBR Safe, with total compensation of approximately $165,000 and $90,000, respectively.
  • The company had related party notes payable of $11,810 as of December 31, 2023.

Stakeholder Impact

  • Shareholders face the risk of further dilution and potential loss of investment due to the company's financial situation.
  • Employees may be affected by potential cost-cutting measures.
  • Customers may be impacted by potential supply chain issues or product defects.
  • Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

  • The company will continue to focus on generating product and service revenues.
  • The company will continue to explore licensing and integration opportunities.
  • The company will continue to monitor and improve its internal controls.
  • The company will continue to evaluate opportunities to increase its stockholders equity.
  • The company will continue to monitor the closing bid price of its common stock and may consider options to regain compliance with Nasdaq listing requirements.

Key Dates

DateDescription
2007-08-10SOBR Safe, Inc. was incorporated in Delaware.
2011-09-19Imagine Media, Ltd. acquired approximately 52% of TransBiotec, Inc.
2020-03-09Board of Directors approved the amendment to the Certificate of Incorporation to change the name to SOBR Safe, Inc.
2020-04-24Certificate of Amendment to the Certificate of Incorporation became effective with the State of Delaware.
2022-04-281-for-3 reverse split of common stock went effective with the OTC Markets.
2022-05-16Common stock began trading on the Nasdaq Capital Market.
2023-09SOBRsure wearable band device became commercially available.
2023-10Commercial sales of the SOBRsure device commenced.
2024-03-29Date of the report, with 20,007,465 shares of common stock issued and outstanding.

Keywords

alcohol detection, wearable technology, biometric, SaaS, fleet management, workplace safety, behavioral health, transdermal, SOBRsafe, SOBRcheck, SOBRsure

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.